Aprocitentan is a Dual ET-1 Antagonist for Hypertension Research
On March 19, 2024, the U.S. Food and Drug Administration recently granted approval to Aprocitentan. Aprocitentan is a new medication aimed at addressing refractory hypertension in adults. Aprocitentan, a dual…